Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Paul Lorigan"'
Autor:
Richard Marais, Grazia Saturno, Robert McLeary, Cyril Fisher, Udai Banerji, Alfonso Zambon, Lawrence Davies, Rebecca Lee, J.M.G. Larkin, Natasha Preece, Emma Dean, Paul Lorigan, Dan Niculescu-Duvaz, Matthew G Krebs, Amaya Viros, Nathalie Dhomen, Malin Pedersen, L. Johnson, Filipa Lopes, Caroline J. Springer, D. Holovanchuk, M. E. Gore, Ion Niculescu-Duvaz
Publikováno v:
Annals of Oncology
Saturno, G, Lopes, F, Niculescu-Duvaz, I, Niculescu-Duvaz, D, Zambon, A, Davies, L, Johnson, L, Preece, N, Lee, R, Viros Usandizaga, A, Holovanchuk, D, Pedersen, M, Mcleary, R, Lorigan, P, Dhomen, N, Fisher, C, Banerji, U, Dean, E, Krebs, M, Gore, M, Larkin, J, Marais, R & Springer, C 2021, ' The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers ', Annals of Oncology, vol. 32, no. 2, pp. 269-278 . https://doi.org/10.1016/j.annonc.2020.10.483
Saturno, G, Lopes, F, Niculescu-Duvaz, I, Niculescu-Duvaz, D, Zambon, A, Davies, L, Johnson, L, Preece, N, Lee, R, Viros Usandizaga, A, Holovanchuk, D, Pedersen, M, Mcleary, R, Lorigan, P, Dhomen, N, Fisher, C, Banerji, U, Dean, E, Krebs, M, Gore, M, Larkin, J, Marais, R & Springer, C 2021, ' The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers ', Annals of Oncology, vol. 32, no. 2, pp. 269-278 . https://doi.org/10.1016/j.annonc.2020.10.483
Background KRAS is mutated in ∼90% of pancreatic ductal adenocarcinomas, ∼35% of colorectal cancers and ∼20% of non-small-cell lung cancers. There has been recent progress in targeting G12CKRAS specifically, but therapeutic options for other mu
Autor:
Iwona Lugowska, C. Gaudy-Marqueste, J.-J. Grob, Marco Donia, Paul Nathan, Bart Neyns, Mark B. Faries, Piotr Rutkowski, A.C.J. van Akkooi, Vernon K. Sondak, Bastian Schilling, Andrew J. Hayes, Christoph Hoeller, Ulrich Keilholz, P.A. Ascierto, J.B.A.G. Haanen, Matthias Guckenberger, Vanna Chiarion Sileni, C. Lebb, R. Dummer, C. Blank, H.A. Tawbi, Olivier Michielin, M. Mandal, Paul Lorigan, S. Puig, Helen Gogas, C. Robert, A. Testori, Roger Olofsson Bagge, Ivan Marquez-Rodas, A. Arance
The European Society for Medical Oncology (ESMO) held a consensus conference on melanoma on 5-7 September 2019 in Amsterdam, The Netherlands. The conference included a multidisciplinary panel of 32 leading experts in the management of melanoma. The a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d438208159b4c1b725206a4fa08d0f2
https://biblio.vub.ac.be/vubir/(429bf7ef-2b66-47de-adff-ca831dbc52a1).html
https://biblio.vub.ac.be/vubir/(429bf7ef-2b66-47de-adff-ca831dbc52a1).html